Sign on San Diego -- Isis Pharmaceuticals said it reacquired the rights to a cancer drug it had licensed to Eli Lilly & Co. Carlsbad-based Isis said it is reinvigorating its internal cancer program and will make the drug it is reacquiring the first drug in development under the new initiative. It will look at the drug in multiple types of cancer, potentially including breast, lung, prostate, bladder and colon cancers.
